Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis.

Malucchi, S

Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis. [electronic resource] - Neurology Jun 2004 - 2031-7 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1526-632X

10.1212/01.wnl.0000129265.73259.9e doi


Adolescent
Adult
Aged
Antibody Specificity
Antiviral Agents--immunology
Cell Line, Tumor
Cytopathogenic Effect, Viral--drug effects
Disease Progression
Disease-Free Survival
Drug Resistance
Encephalomyocarditis virus--drug effects
Female
Follow-Up Studies
Humans
Incidence
Interferon beta-1a
Interferon beta-1b
Interferon-beta--antagonists & inhibitors
Isoantibodies--immunology
Life Tables
Male
Middle Aged
Multiple Sclerosis, Relapsing-Remitting--drug therapy
Neutralization Tests
Prospective Studies
Severity of Illness Index
Treatment Outcome